Abstract
We report the results of a prospective Italian multi-center study of the effects of lanreotide, a slow-release somatostatin analog, on left ventricular morphology and function and on the prevalence of ventricular arrhythmic events in 19 patients with active, newly diagnosed, uncomplicated acromegaly. Cardiac features were evaluated with Doppler-echocardiography and 24-h Holter ECG monitoring at baseline and after 6 months of lanreotide therapy. Fifteen patients (78.9%) had left ventricular hypertrophy. Lanreotide treatment significantly decreased the left ventricular mass (127.8±6.9 vs 140.7±7.1 g/m2, p50/24 h) occurred in 16.6% of patients and were unaffected by treatment. Differently, ventricular premature beats (>50/24 h) occurred in 33.3% of patients before treatment vs 16.5%, after treatment. In conclusion, lanreotide reduced the left ventricular mass, and improved ventricular filling and ventricular arrhythmic profile.
Original language | English |
---|---|
Pages (from-to) | 971-976 |
Number of pages | 6 |
Journal | Journal of Endocrinological Investigation |
Volume | 25 |
Issue number | 11 |
Publication status | Published - Dec 2002 |
Keywords
- Acromegaly
- Arrhythmias
- GH
- Hypertrophy
- IGF-I
- Lanreotide
ASJC Scopus subject areas
- Endocrinology